News

Show
news from

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases

OMass CEO Ros Deegan Named as a 2022 In Vivo Rising Leader

Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane Environment

OMass Establishes Scientific Advisory Board of Leading Experts in the Use of Biophysical Approaches to Drug Discovery

OMass’s OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D

OMass Therapeutics to Present at Upcoming Conferences

Load more

Search